Oligonucleotides News and Research

RSS

Oligonucleotides are short sequences of nucleotides (RNA or DNA), typically with twenty or fewer bases. Automated synthesizers allow the synthesis of oligonucleotides up to 160 to 200 bases.

Affomix, City of Hope collaborate in exploring next generation sequencing using digital proteomics

Affomix Corporation, a pioneer in high performance antibody technology, announced today a collaboration with City of Hope focused on establishing the clinical utility of “digital proteomics” with next generation sequencers. One of the nation’s top cancer research and treatment centers, City of Hope is a leading provider of molecular diagnostic testing services and an innovator in clinical genetics research.

19 Jan 2010

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

Regulus Therapeutics Inc. today announced that new pre-clinical data from multiple therapeutic programs were presented at the “RNA Silencing: Mechanism, Biology and Application” Keystone Symposium held January 14 – 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing microRNA target regulation by anti-miRs, as well as data from therapeutic programs focused on oncology, immune disease and hepatitis C virus (HCV) infection.

18 Jan 2010

TriLink BioTechnologies and tebu-bio SA sign distribution agreement

TriLink BioTechnologies, Inc. (TriLink), a leading provider of custom nucleic acid-based compounds, announced it has signed a distribution agreement permitting tebu-bio SA (tebu) to sell its CleanAmp(TM) products. tebu-bio is a European based distributor that supplies over 750,000 reagents and lab services from manufacturers worldwide.

12 Jan 2010

Annelie Wendeberg presents protocol for identification of environmental microbes

Metagenomics, the study of DNA isolated from samples of naturally occurring microbial populations, is rapidly growing. Improvements to cloning and sequencing techniques are allowing researchers to study microorganisms in environmental samples, and new knowledge of species interactions and community dynamics is emerging.

5 Jan 2010

Dicerna Pharmaceuticals and Kyowa Hakko Kirin sign research collaboration and license agreement

Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules, and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), one of Japan's leading biopharmaceutical companies, announced today that the two companies have entered into a research collaboration and license agreement for the research, development and commercialization of drug delivery systems and DsiRNA pharmaceuticals for therapeutic targets in oncology.

4 Jan 2010

Regado Biosciences announces completion of Series D financing

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced the completion of a $40 million Series D financing.

18 Dec 2009

Regulus Therapeutics wins exclusive rights to modulate microRNAs

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., announced today that it has obtained exclusive rights from the California Institute of Technology to inventions made in the laboratory of David Baltimore, Ph.D. covering methods and compositions for modulating microRNA-146 and microRNA-155.

18 Dec 2009

USPTO issues Notice of Allowance for U.S. patent application in the 'Crooke' patent family

Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application (No. 10/078,949) in the “Crooke” patent family, which broadly covers chemically modified RNA-containing therapeutics.

16 Dec 2009

Regulus Therapeutics to host educational webinar about microRNA biology

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc., unveiled plans for an educational webinar about microRNA biology that will highlight several recent exciting discoveries in the field and showcase the therapeutic strategies based on microRNA.

10 Dec 2009

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

A study published online in this week's Science shows that SPC3649, a breakthrough microRNA-targeted therapy developed by Santaris Pharma A/S using its proprietary Locked Nucleic Acid (LNA) technology, holds promise as a novel treatment for patients infected with the Hepatitis C virus (HCV).

4 Dec 2009

Kyto advancing with a program for humanization of the mAbTCR23 antibody

Kyto Biopharma Inc., is a biotechnology company focused on developing monoclonal antibody and oligonucleotide targeting therapeutics based on a proprietary vitamin B12 platform for the treatment of various forms of cancer.

4 Dec 2009

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Isis Pharmaceuticals, Inc. announced today that it has added two new drugs to its development pipeline, ISIS-FXIRx and ISIS-SMNRx.

4 Dec 2009

NOXXON Pharma achieves important milestone in drug discovery

NOXXON Pharma AG (NOXXON), the biopharmaceutical company focusing on the development of novel medicines based on its unique proprietary Spiegelmer® technology, announced today the achievement of an important milestone in its drug discovery and development partnership with Eli Lilly and Company.

3 Dec 2009

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

Previous studies have indicated that the heparanase (HPA) is correlated with histopathological parameters and poor prognosis of gastric cancers. Although their efficiencies in inhibiting the expression of HPA, the traditional HPA inhibitors may produce nonspecific and undesirable effects. In recent years, genetic approaches targeting HPA have been regarded as a promising alternative.

25 Nov 2009

Novartis to terminate its research collaboration agreement with Idera Pharmaceuticals

Idera Pharmaceuticals, Inc., today announced that Novartis will terminate its research collaboration agreement with the Company, effective as of February 21, 2010.

25 Nov 2009

Bioniche Life Sciences announces the issuance of MCC patents in Japan

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced the issuance of a number of patents in Japan for its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) composition.

25 Nov 2009

RXi Pharmaceuticals announces financial results for the quarter ended September 30, 2009

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported its financial results for the quarter ended September 30, 2009.

16 Nov 2009

PPMD awards $75,000 grant to University of California professor for Duchenne muscular dystrophy research

Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced today the latest recipient of the End Duchenne Grant Award Program.

6 Nov 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.

5 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

Oligonucleotides News and Research

Further Reading

Affomix, City of Hope collaborate in exploring next generation sequencing using digital proteomics

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

TriLink BioTechnologies and tebu-bio SA sign distribution agreement

Annelie Wendeberg presents protocol for identification of environmental microbes

Dicerna Pharmaceuticals and Kyowa Hakko Kirin sign research collaboration and license agreement

Regado Biosciences announces completion of Series D financing

Regulus Therapeutics wins exclusive rights to modulate microRNAs

USPTO issues Notice of Allowance for U.S. patent application in the 'Crooke' patent family

Regulus Therapeutics to host educational webinar about microRNA biology

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

Kyto advancing with a program for humanization of the mAbTCR23 antibody

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

NOXXON Pharma achieves important milestone in drug discovery

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

Novartis to terminate its research collaboration agreement with Idera Pharmaceuticals

Bioniche Life Sciences announces the issuance of MCC patents in Japan

RXi Pharmaceuticals announces financial results for the quarter ended September 30, 2009

PPMD awards $75,000 grant to University of California professor for Duchenne muscular dystrophy research

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Biochemistry eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News